A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)
Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Primary Cutaneous Follicle Centre Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Mantle Cell Lymphoma|Plasma Cell Neoplasm|B Cell Lymphoma
DRUG: Autologous chimeric antigen receptor T cell transfusing agent targeting CD22
Adverse Events That Are Related to Treatment, Determine the toxicity profile of the CD22 targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.03, 2 years|The effect after treatment, ORR within 24 weeks after infusion （CR+CRi）, 24 weeks
In vivo existence of Anti-CD22 CAR-T cells, 2 years
Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)